Response assessment criteria and their applications in lymphoma: Part 1

Mateen C. Moghbel, Lale Kostakoglu, Katherine Zukotynski, Delphine L. Chen, Helen Nadel, Ryan Niederkohr, Erik Mittra

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.

Original languageEnglish
Pages (from-to)928-935
Number of pages8
JournalJournal of Nuclear Medicine
Volume57
Issue number6
DOIs
StatePublished - Jun 1 2016

Keywords

  • CT
  • Lymphoma
  • PERCIST
  • PET
  • RECIST

Fingerprint Dive into the research topics of 'Response assessment criteria and their applications in lymphoma: Part 1'. Together they form a unique fingerprint.

  • Cite this

    Moghbel, M. C., Kostakoglu, L., Zukotynski, K., Chen, D. L., Nadel, H., Niederkohr, R., & Mittra, E. (2016). Response assessment criteria and their applications in lymphoma: Part 1. Journal of Nuclear Medicine, 57(6), 928-935. https://doi.org/10.2967/jnumed.115.166280